Crystalline forms of ras inhibitors, compositions containing the same, and methods of use thereof
US-2024352036-A1 · Oct 24, 2024 · US
Pyrazolopyrimidine macrocycles as inhibitors of human immunodeficiency virus replication
US10125148B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-10125148-B2 |
| Application number | US-201415119475-A |
| Country | US |
| Kind code | B2 |
| Filing date | Feb 19, 2014 |
| Priority date | Feb 19, 2014 |
| Publication date | Nov 13, 2018 |
| Grant date | Nov 13, 2018 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The disclosure generally relates to compounds of formula I, including compositions and methods for treating human immunodeficiency virus (HIV) infection. The disclosure provides novel inhibitors of HIV, pharmaceutical compositions containing such compounds, and methods for using these compounds in the treatment of HIV infection.
First claim
Opening claim text (preview).
We claim: 1. A compound or salt selected from the group consisting of (2S)-2-(tert-Butoxy)-2-[(22S)-4,22,28-trimethyl-17-(trifluoromethyl)-21,27-dioxa-1,5,7,8-tetraazahexacyclo[26.2.2.1 6,9 .1 10,14 .0 2,7 .0 15,20 ]tetratriaconta-2,4,6(34),8,10(33),11,13,15(20),16,18-decaen-3-yl]acetic acid; (2S)-2-(tert-Butoxy)-2-[(22S)-17,18-difluoro-4,22,28-trimethyl-21,27-dioxa-1,5,7,8-tetraazahexacyclo[26.2.2.1 6,9 .1 10,14 .0 2,7 .0 15,20 ]tetratriaconta-2,4,6(34),8,10(33),11,13,15(20),16,18-decaen-3-yl]acetic acid; (2S)-2-(tert-Butoxy)-2-[(22S)-16,18-difluoro-4,22,28-trimethyl-21,27-dioxa-1,5,7,8-tetraazahexacyclo[26.2.2.1 6,9 .1 10,14 .0 2,7 .0 15,20 ]tetratriaconta-2,4,6(34),8,10(33),11,13,15(20),16,18-decaen-3-yl]acetic acid; (2S)-2-(tert-Butoxy)-2-[(22S,24E)-16-fluoro-4,18,22,28-tetramethyl-21,27-dioxa-1,5,7,8-tetraazahexacyclo[26.2.2.1 6,9 .1 10,14 .0 2,7 .0 15,20 ]tetratriaconta-2,4,6(34),8,10(33),11,13,15(20),16,18,24-undecaen-3-yl]acetic acid; (2S)-2-(tert-Butoxy)-2-[(22S)-16-fluoro-4,18,22,28-tetramethyl-21,27-dioxa-1,5,7,8-tetraazahexacyclo[26.2.2.1 6,9 .1 10,14 .0 2,7 .0 15,20 ]tetratriaconta-2,4,6(34),8,10(33),11,13,15(20),16,18-decaen-3-yl]acetic acid; (2S)-2-(tert-Butoxy)-2-[(22S)-17-ethyl-4,22,28-trimethyl-21,27-dioxa-1,5,7,8-tetraazahexacyclo[26.2.2.1 6,9 .1 10,14 .0 2,7 .0 15,20 ]tetratriaconta-2,4,6(34),8,10(33),11,13,15(20),16,18,24-undecaen-3-yl]acetic acid; (2S)-2-(tert-Butoxy)-2-[(22S)-17-ethyl-4,22,28-trimethyl-21,27-dioxa-1,5,7,8-tetraazahexacyclo[26.2.2.1 6,9 .1 10,14 .0 2,7 .0 15,20 ]tetratriaconta-2,4,6(34),8,10(33),11,13,15(20),16,18-decaen-3-yl]acetic acid; (2S)-2-(tert-Butoxy)-2-[(22S)-17-methoxy-4,22,28-trimethyl-21,27-dioxa-1,5,7,8-tetraazahexacyclo[26.2.2.1 6,9 .1 10,14 .0 2,7 .0 15,20 ]tetratriaconta-2,4,6(34),8,10(33),11,13,15(20),16,18-decaen-3-yl]acetic acid; (2S)-2-(tert-Butoxy)-2-[(23E)-18-fluoro-4,22,27-trimethyl-21,26-dioxa-1,5,7,8-tetraazahexacyclo[25.2.2.1 6,9 .1 10,14 .0 2,7 .0 15,20 ]tritriaconta-2,4,6(33),8,10(32),11,13,15(20),16,18,23-undecaen-3-yl]acetic acid; (2S)-2-(tert-Butoxy)-2-[(22S)-18-fluoro-4,22,27-trimethyl-21,26-dioxa-1,5,7,8-tetraazahexacyclo[25.2.2.1 6,9 .1 10,14 .0 2,7 .0 15,20 ]tritriaconta-2,4,6(33),8,10(32),11,13,15(20),16,18-decaen-3-yl]acetic acid; (2S)-2-(tert-Butoxy)-2-[(22S,23E)-16-fluoro-4,17,22,27-tetramethyl-21,26-dioxa-1,5,7,8-tetraazahexacyclo[25.2.2.1 6,9 .1 10,14 .0 2,7 .0 15,20 ]tritriaconta-2,4,6(33),8,10(32),11,13,15(20),16,18,23-undecaen-3-yl]acetic acid; (2S)-2-(tert-Butoxy)-2-[(22S)-16-fluoro-4,17,22,27-tetramethyl-21,26-dioxa-1,5,7,8-tetraazahexacyclo[25.2.2.1 6,9 .1 10,14 .0 2,7 .0 15,20 ]tritriaconta-2,4,6(33),8,10(32),11,13,15(20),16,18-decaen-3-yl]acetic acid; (2S)-2-(tert-Butoxy)-2-[(22S,23E)-17-fluoro-4,22,27-trimethyl-21,26-dioxa-1,5,7,8-tetraazahexacyclo[25.2.2.1 6,9 .1 10,14 .0 2,7 .0 15,20 ]tritriaconta-2,4,6(33),8,10(32),11,13,15(20),16,18,23-undecaen-3-yl]acetic acid; (2S)-2-(tert-Butoxy)-2-[(22S)-17-fluoro-4,22,27-trimethyl-21,26-dioxa-1,5,7,8-tetraazahexacyclo[25.2.2.1 6,9 .1 10,14 .0 2,7 .0 15,20 ]tritriaconta-2,4,6(33),8,10(32),11,13,15(20),16,18-decaen-3-yl]acetic acid; (2S)-2-(tert-Butoxy)-2-[(22S,23E)-4,18,22,27-tetramethyl-21,26-dioxa-1,5,7,8-tetraazahexacyclo[25.2.2.1 6,9 .1 10,14 .0 2,7 .0 15,20 ]tritriaconta-2,4,6(33),8,10(32),11,13,15(20),16,18,23-undecaen-3-yl]acetic acid; (2S)-2-(tert-Butoxy)-2-[(22S)-4,18,22,27-tetramethyl-21,26-dioxa-1,5,7,8-tetraazahexacyclo[25.2.2.1 6,9 .1 10,14 .0 2,7 .0 15,20 ]tritriaconta-2,4,6(33),8,10(32),11,13,15(20),16,18-decaen-3-yl]acetic acid; (2S)-2-(tert-Butoxy)-2-[(22S,23E)-16-fluoro-4,18,22,27-tetramethyl-21,26-dioxa-1,5,7,8-tetraazahexacyclo[25.2.2.1 6,9 .1 10,14 .0 2,7 .0 15,20 ]tritriaconta-2,4,6(33),8,10(32),11,13,15(20),16,18,23-undecaen-3-yl]acetic acid; (2S)-2-(tert-Butoxy)-2-[(22S)-16-fluoro-4,18,22,27-tetramethyl-21,26-dioxa-1,5,7,8-tetraazahexacyclo[25.2.2.1 6,9 .1 10,14 .0 2,7 .0 15,20 ]tritriaconta-2,4,6(33),8,10(32),11,13,15(20),16,18-decaen-3-yl]acetic acid; (2S)-2-(tert-Butoxy)-2-[(22S,25Z)-4,17,22,28-tetramethyl-21,27-dioxa-1,5,7,8-tetraazahexacyclo[26.2.2.1 6,9 .1 10,14 .0 2,7 .0 15,20 ]tetratriaconta-2,4,6(34),8,10(33),11,13,15(20),16,18,25-undecaen-3-yl]acetic acid; (2S)-2-(tert-Butoxy)-2-[(22S)-4,17,22,28-tetramethyl-21-oxa-1,5,7,8-tetraazahexacyclo[26.2.2.1 6,9 .1 10,14 .0 2,7 .0 15,20 ]tetratriaconta-2,4,6(34),8,10(33),11,13,15(20),16,18,24-undecaen-3-yl]acetic acid; (2S)-2-(tert-Butoxy)-2-[(22S)-4,17,22,28-tetramethyl-21-oxa-1,5,7,8-tetraazahexacyclo[26.2.2.1 6,9 .1 10,14 .0 2,7 .0 15,20 ]tetratriaconta-2,4,6(34),8,10(33),11,13,15(20),16,18-decaen-3-yl]acetic acid; (2S)-2-(tert-Butoxy)-2-[(22S)-17-cyano-4,22,28-trimethyl-21-oxa-1,5,7,8-tetraazahexacyclo[26.2.2.1 6,9 .1 10,14 .0 2,7 .0 15,20 ]tetratriaconta-2,4,6(34),8,10(33),11,13,15(20),16,18,24-undecaen-3-yl]acetic acid; (2S)-2-(tert-Butoxy)-2-[(22S)-17-cyano-4,22,28-trimethyl-21-oxa-1,5,7,8-tetraazahexacyclo[26.2.2.1 6,9 .1 10,14 .0 2,7 .0 15,20 ]tetratriaconta-2,4,6(34),8,10(33),11,13,15(20),16,18-decaen-3-yl]acetic acid; (2S)-2-(tert-butoxy)-2-[(22S)-17-carbamoyl-4,22,28-trimethyl-21-oxa-1,5,7,8-tetraazahexacyclo[26.2.2.1 6,9 .1 10,14 .0 2,7 .0 15,20 ]tetratriaconta-2,4,6(34),8,10(33),11,13,15(20),16,18-decaen-3-yl]acetic acid; (2S)-2-(tert-Butoxy)-2-[(22S)-17-[(3,3-dimethylbutyl)carbamoyl]-4,22,28-trimethyl-21,27-dioxa-1,5,7,8-tetraazahexacyclo[26.2.2.1 6,9 .1 10,14 .0 2,7 .0 15,20 ]tetratriaconta-2,4,6(34),8,10(33),11,13,15(20),16,18-decaen-3-yl]acetic acid; (2S)-2-(tert-Butoxy)-2-[(22S)-11,18-difluoro-4,22,28-trimethyl-21,27-dioxa-1,5,7,8-tetraazahexacyclo[26.2.2.1 6,9 .1 10,14 .0 2,7 .0 15,20 ]tetratriaconta-2,4,6(34),8,10(33),11,13,15(20),16,18-decaen-3-yl]acetic acid; (2S)-2-(tert-Butoxy)-2-[(22S)-12,18-difluoro-4,22,28-trimethyl-21,27-dioxa-1,5,7,8-tetraazahexacyclo[26.2.2.1 6,9 .1 10,14 .0 2,7 .0 15,20 ]tetratriaconta-2,4,6(34),8,10(33),11,13,15(20),16,18-decaen-3-yl]acetic acid; (2S)-2-(tert-Butoxy)-2-[(22S)-13,18-difluoro-4,22,28-trimethyl-21,27-dioxa-1,5,7,8-tetraazahexacyclo[26.2.2.1 6,9 .1 10,14 .0 2,7 .0 15,20 ]tetratriaconta-2,4,6(34),8,10(33),11,13,15(20),16,18-decaen-3-yl]acetic acid; (2S)-2-(tert-Butoxy)-2-[(22S)-4,16,17,22,27-pentamethyl-21,26-dioxa-1,5,7,8-tetraazahexacyclo[25.2.2.1 6,9 .1 10,14 .0 2,7 .0 15,20 ]tritriaconta-2,4,6(33),8,10(32),11,13,15(20),16,18,23-undecaen-3-yl]acetic acid; (2S)-2-(tert-Butoxy)-2-[(22S)-4,16,17,22,27-pentamethyl-21,26-dioxa-1,5,7,8-tetraazahexacyclo[25.2.2.1 6,9 .1 10,14 .0 2,7 .0 15,20 ]tritriaconta-2,4,6(33),8,10(32),11,13,15(20),16,18-decaen-3-yl]acetic acid; (2S)-2-(tert-Butoxy)-2-[(22S)-17-fluoro-4,16,22,27-tetramethyl-21,26-dioxa-1,5,7,8-tetraazahexacyclo[25.2.2.1 6,9 .1 10,14 .0 2,7 .0 15,20 ]tritriaconta-2,4,6(33),8,10(32),11,13,15(20),16,18,23-undecaen-3-yl]acetic acid; (2S)-2-(tert-Butoxy)-2-[(22S)-17-fluoro-4,16,22,27-tetramethyl-21,26-dioxa-1,5,7,8-tetraazahexacyclo[25.2.2.1 6,9 .1 10,14 .0 2,7 .0 15,20 ]tritriaconta-2,4,6(33),8,10(32),11,13,15(20),16,18-decaen-3-yl]acetic acid; (2S)-2-(tert-Butoxy)-2-[(22S)-16,18-difluoro-4,22,27-trimethyl-21,26-dioxa-1,5,7,8-tetraazahexacyclo[25.2.2.1 6,9 .1 10,14 .0 2,7 .0 15,20 ]tritriaconta-2,4,6(33),8,10(32),11,13,15(20),16,18,23-undecaen-3-yl]acetic acid; (2S)-2-(tert-Butoxy)-2-[(22S)-16,18-difluoro-4,22,27-trimethyl-21,26-dioxa-1,5,7,8-tetraazahexacyclo[25.2.2.1 6,9 .1 10,14 .0 2,7 .0 15,20 ]tritriaconta-2,4,6(33),8,10(32),11,13,15(20),16,18-decaen-3-yl]acetic acid; (2S)-2-(tert-Butoxy)-2-[(22S)-4,17,18,22,27-pentamethyl-21,26-dioxa-1,5,7,8-tetraazahexacyclo[25.2.2.1 6,9 .1 10,14 .0 2,7 .0 15,20 ]tritriaconta-2,4,6(33),8,10(32),11,13,15(20),16,18,23-undecaen-3-yl]acetic acid; (2S)-2-(tert-Butoxy)-2-[(22S)-4,17,18,22,27-pentamethyl-21,26-dioxa-1,5,7,8-tetraazahexacyclo[25.2.2.1 6,9 .1 10,14 .0 2,7 .0 15,20 ]tritriaconta-2,4,6(33),8,10(32),11,13,15(20),16,18-decaen-3-yl]acetic acid; (2S)-2-(tert-Butoxy)-2-[(22S)-17-fluoro-4,18,22,27-tetramethyl-
Assignees
Inventors
Classifications
for HIV · CPC title
- C07D498/22Primary
in which the condensed system contains four or more hetero rings · CPC title
Peri-condensed systems · CPC title
Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca · CPC title
ortho- or peri-condensed with heterocyclic rings · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US10125148B2 cover?
- The disclosure generally relates to compounds of formula I, including compositions and methods for treating human immunodeficiency virus (HIV) infection. The disclosure provides novel inhibitors of HIV, pharmaceutical compositions containing such compounds, and methods for using these compounds in the treatment of HIV infection.
- Who is the assignee on this patent?
- Viiv Healthcare Uk No 5 Ltd
- What technology area does this patent fall under?
- Primary CPC classification C07D498/22. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Nov 13 2018 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).